2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Treatment Considerations, Supportive Care, Therapy Sequence, Biological Therapies, Transfusion, Non-Biological Therapies, Anticoagulant Drugs, Pharmacology, Women’s Health, Workforce, Adverse Events, Clinical Practice (Health Services and Quality), Health Economics, Patient Safety, Quality Improvement, Quality of Care, Systems-Based Hematology, Value, Diseases, Bleeding and Clotting, Hemophilia, Thromboembolism, Thrombotic Disorders, Bone Marrow Failure Syndromes, Paroxysmal Nocturnal Hemoglobinuria, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Metabolic Disorders, Iron Deficiency, Iron Overload, B Cell Lymphoma, Research, Clinical Research, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

4374 Evaluation of hormonal therapy management and outcomes in reproductive-age women initiating oral anticoagulation for acute venous thromboembolism treatment

Mackenzie Emily Lemieux, MD, Spencer Gilbert, PharmD2, Stephen Jenkins, MD3, Sara Vazquez, PharmD4, Ming Lim, MBBCh, MS5
1 University of Utah Huntsman Center, Salt Lake City, United States
2 University of Utah Huntsman Center, Salt Lake City, United States
3 University of Utah Huntsman Center, Salt Lake City, United States
4 University of Utah Huntsman Center, Salt Lake City, United States
5 University of Utah Huntsman Center, Salt Lake City, United States

Background

Abnormal uterine bleeding (AUB) occurs in two thirds of reproductive age women on anticoagulation, negatively impacting their quality of life (de Jong et al. 2022; Liu et al. 2007). Management of estrogen-containing hormonal therapies in women newly diagnosed with venous thromboembolism (VTE) remains inconsistent despite contemporary guidance supporting continuation of hormonal therapy with initiation of therapeutic anticoagulation (Klok et al. 2017; Martinelli et al. 2016; Samuelson Bannow et al. 2025). Inappropriate discontinuation of estrogen-containing hormonal therapy increases rates of AUB, iron deficiency, and anemia (Samuelson Bannow et al. 2025). We seek to determine the current practice pattern for hormonal therapy management among reproductive-age women diagnosed with acute VTE and its associated outcomes.

Methods

We performed a single-center retrospective cohort study of reproductive age women (18–55 years) diagnosed with acute VTE at the University of Utah Health between January 2015 and December 2024. VTE events were identified using validated natural language processing algorithms applied to radiographic reports (Johnson et al. 2021; Woller et al. 2021). Women prescribed oral anticoagulation within 7 days of VTE diagnosis and estrogen-containing hormonal therapy within 1 year prior to the VTE event were included. For individuals with multiple VTE events during the study period, only the earliest qualifying VTE event was included.

Clinical, laboratory, and prescribing data were extracted from the electronic medical record and supplemented by manual chart review. Primary outcomes included rates of estrogen-containing hormonal therapy continuation, discontinuation, or transition to a different hormonal therapy following the VTE event. Secondary outcomes included rates of AUB, emergency department (ED) visits for AUB, anemia (defined as <12 g/dL), iron deficiency (defined as ferritin <30 ng/mL), and laboratory monitoring for anemia and iron deficiency within 3 months post-VTE diagnosis.

Results

Among 870 reproductive-age women prescribed oral anticoagulation following an acute VTE, 83 women met inclusion criteria. The median age was 32 years (range 19–54), and 52% (n= 43) had a history of AUB. Estrogen-containing hormonal therapy was discontinued in 45% (n=37) of women, continued in 18% (n=15), discontinued with immediate (<1 week) transition to a non-estrogen containing alternative contraceptive strategy in 21% (n = 17), and discontinued with delayed (>=1 week) transition to a non-estrogen containing alternative in 16% (n=13). Among women who immediately transitioned therapy, most initiated progestin-only pills (65%, n=11), while most women with delayed transitions had intrauterine devices (IUDs) placed (56%, n=7).

Laboratory monitoring for iron deficiency and anemia following the VTE event was limited. Hemoglobin assessment within 3 months occurred in only 36% (n=30) of women, while ferritin testing occurred in 17% (n=14). Among women who underwent post-VTE laboratory testing, anemia was identified in 30% (n = 9 out of 30) and iron deficiency in 50% (n = 7 out of 14).

AUB occurred in 45% of women during the first 3 months post-VTE. Rates of AUB were lower among women who continued estrogen-containing hormonal therapy compared with those who discontinued, immediately transitioned, or had a delayed transition of their estrogen-containing hormone therapy (27% vs 35%, 60%, 77% respectively, p=0.018).

Conclusions

Discontinuation of estrogen-containing hormonal therapy at time of VTE diagnosis remains common despite contemporary evidence supporting continuation with initiation of therapeutic anticoagulation. Rates of post-VTE laboratory monitoring for anemia and iron deficiency were also low, despite high rates of AUB and clinically significant hematologic abnormalities among those tested. These findings identify substantial gaps in antithrombotic stewardship and monitoring of iron deficiency among reproductive-age women diagnosed with acute VTE.

Mackenzie Emily Lemieux, MD: No relevant conflicts of interest to declare.